Novartis, Genentech's omalizumab again proves effective in CSU

Novartis (NVS) and Genentech's (RHHBY.OB) persistent allergic asthma treatment omalizumab performs well in ASTERIA I, the last of three Phase 3 registration studies (ASTERIA II and GLACIAL) for the treatment of chronic spontaneous urticaria, a form of hives for which antihistamines are one of the only available treatments.

Patients responded as early as week one compared to week four for placebo and by the twelfth week, all three doses of omalizumab were "significantly superior to placebo in improving patients' weekly Itch Severity Score," the primary endpoint.

ASTERIA I also "met all pre-specified secondary efficacy endpoints" except one. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs